Repligen FY2025 EPS Forecast Increased by Leerink Partnrs

Repligen Corporation (NASDAQ:RGEN - Free Report) - Analysts at Leerink Partnrs raised their FY2025 earnings estimates for Repligen in a note issued to investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will earn $1.68 per share for the year, up from their prior forecast of $1.67. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen's FY2026 earnings at $2.18 EPS.

A number of other research firms have also recently weighed in on RGEN. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a report on Tuesday, April 29th. Evercore ISI cut their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Royal Bank Of Canada reduced their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Canaccord Genuity Group lowered their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $170.75.

Repligen Trading Down 6.3%

RGEN opened at $116.25 on Monday. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The firm has a market cap of $6.53 billion, a price-to-earnings ratio of -258.33, a PEG ratio of 3.32 and a beta of 1.11. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The stock has a fifty day moving average price of $124.65 and a 200-day moving average price of $138.44.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same quarter in the previous year, the business posted $0.28 EPS. The company's quarterly revenue was up 10.4% compared to the same quarter last year.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. KBC Group NV lifted its position in Repligen by 14.9% during the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock valued at $324,000 after purchasing an additional 329 shares during the period. LPL Financial LLC raised its stake in shares of Repligen by 47.6% during the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock valued at $4,873,000 after buying an additional 10,395 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares during the period. GAMMA Investing LLC boosted its stake in shares of Repligen by 40.1% in the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after buying an additional 274 shares during the last quarter. Finally, Zions Bancorporation N.A. boosted its stake in shares of Repligen by 48.9% in the fourth quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company's stock worth $2,027,000 after buying an additional 4,626 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.